Allergy Diagnostics and Therapeutics Market Share, Trends & Market Forecast (2025-2035)

Key Market Highlights

Allergy Diagnostics and Therapeutics Market Size Was Valued at USD 5.86 Billion in 2024, and is Projected to Reach USD 17.93 Billion by 2035, Growing at a CAGR of 10.71% from 2025-2035.

• Market Size in 2024: USD 5.86 Billion
• Projected Market Size by 2035: USD 17.93 Billion
• CAGR (2025–2035): 10.71%
• Leading Market in 2024: North America
• Fastest-Growing Market: Asia-Pacific
• By Type: The Therapeutics segment is anticipated to lead the market by accounting for 57.41% of the market share throughout the forecast period.
• By Allergen: The Pollen segment is expected to capture 25.06% of the market share, thereby maintaining its dominance over the forecast period.
• By Region: North America region is projected to hold 31.26% of the market share during the forecast period.
• Active Players: Thermo Fisher Scientific Inc (US), Canon Inc. (Japan), HollisterStier Allergy (US), Siemens Healthineers AG (Germany), Minaris Medical America Inc (US), BioMérieux SA (France), Omega Diagnostics Group PLC (UK), Danaher (US), Eurofins Scientific (Luxembourg), Stallergenes Greer Ltd (UK), Other Active Players

Allergy Diagnostics And Therapeutics Market Synopsis:

• The Allergy Diagnostics and Therapeutics Market encompass the industry developing and selling tools to identify specific allergies (diagnostics like blood tests, skin pricks) and treatments (therapeutics like antihistamines, immunotherapy, epinephrine) to prevent or manage allergic reactions, driven by rising allergy prevalence, advanced tech, and demand for personalized care. It covers testing kits, instruments, medications, and services for conditions like asthma, rhinitis, food, and drug allergies.

Allergy Diagnostics and Therapeutics Market Dynamics and Trend Analysis:

Allergy Diagnostics and Therapeutics Market Growth Driver - Rising prevalence of allergies worldwide.

• A major growth driver for the Allergy Diagnostics and Therapeutics market is the rising prevalence of allergies worldwide. Changes in lifestyle, urbanization, pollution, and dietary habits have led to an increase in both respiratory and food-related allergies. As more people experience allergic conditions, the demand for accurate diagnostics and effective treatments grows steadily.

• Hospitals, clinics, and diagnostic laboratories are seeing higher patient visits for allergy testing and therapy. This widespread increase in allergy cases encourages pharmaceutical and diagnostic companies to develop new tests, drugs, and immunotherapies, fuelling overall market growth and innovation in the sector.

Allergy Diagnostics and Therapeutics Market Limiting Factor- High cost of advanced diagnostic tests and specialized therapies

• A major limiting factor for the Allergy Diagnostics and Therapeutics market is the high cost of advanced diagnostic tests and specialized therapies. Many in-vitro tests, molecular diagnostics, and immunotherapies are expensive, making them less accessible in developing regions or for patients without adequate insurance coverage.

• Additionally, the lack of awareness about allergy testing and proper treatment in certain populations further restricts market adoption. These factors together limit the growth potential, especially in price-sensitive markets, despite the increasing prevalence of allergies and demand for effective diagnostics and treatments globally.

Allergy Diagnostics and Therapeutics Market Expansion Opportunity- Growing adoption of advanced and personalized diagnostic technologies

• A significant expansion opportunity in the Allergy Diagnostics and Therapeutics market lies in the growing adoption of advanced and personalized diagnostic technologies. Innovations such as component-resolved diagnostics, molecular allergy testing, and point-of-care devices enable faster, more accurate detection of allergens. These technologies allow healthcare providers to offer tailored treatments, improving patient outcomes.

• Expanding awareness and accessibility of such advanced diagnostics in emerging markets, like Asia-Pacific and Latin America, can further drive growth. Companies investing in affordable, user-friendly testing solutions and immunotherapies have a strong opportunity to capture new patient segments and expand their market presence globally.

Allergy Diagnostics and Therapeutics Market Challenge and Risk- Regulatory complexity and stringent approval processes for new diagnostics and therapies

• A major challenge and risk in the Allergy Diagnostics and Therapeutics market is the regulatory complexity and stringent approval processes for new diagnostics and therapies. Developing and launching allergy tests, drugs, or immunotherapies requires extensive clinical trials and compliance with regulations in different countries, which can delay market entry and increase costs.

• Additionally, the risk of inaccurate test results or adverse reactions to treatments can affect patient safety and brand reputation. These regulatory and safety hurdles create barriers for new entrants and limit rapid expansion, especially in markets with strict healthcare compliance requirements.

Allergy Diagnostics and Therapeutics Market Trend- Rising adoption of immunotherapy and biologic treatments.

• An emerging trend in the Allergy Diagnostics and Therapeutics market is the rising adoption of immunotherapy and biologic treatments. Unlike traditional symptomatic drugs, immunotherapy targets the root cause of allergies by gradually desensitizing patients or modulating the immune response. Biologic therapies, such as monoclonal antibodies, are increasingly used for severe or chronic allergic conditions like asthma and atopic dermatitis.

• This shift toward disease-modifying treatments reflects a focus on long-term management rather than short-term relief. Growing awareness among healthcare providers and patients, along with ongoing research, is accelerating the adoption of these advanced therapies worldwide, shaping the future of allergy care.

Allergy Diagnostics and Therapeutics Market Segment Analysis:

Allergy Diagnostics and Therapeutics Market is segmented based on Type, Allergens type, End-Users, and Region

By Type, Therapeutics segment is expected to dominate the market with around 57.41% share during the forecast period.

In the Allergy Diagnostics and Therapeutics market, the Therapeutics segment holds the largest share. This is because most allergy patients need ongoing treatment, such as antihistamines, corticosteroids, or immunotherapy, which generates continuous demand. Treatments are widely used in hospitals, clinics, and pharmacies, making therapeutics the main revenue driver. While diagnostics, including skin tests and blood tests, are growing rapidly due to technological advances, they currently contribute less to total market revenue. Overall, therapeutics dominate because they address immediate symptoms and long-term management, ensuring consistent market demand.

By Allergen, Pollen is expected to dominate with close to 25.06% market share during the forecast period.

Pollen-related allergies, such as hay fever and seasonal allergic rhinitis, affect many people worldwide, making it the most common type of allergy. These allergies are triggered by airborne particles like tree, grass, and weed pollen, which occur seasonally and affect both children and adults. Because of the high prevalence and recurring nature of pollen allergies, there is consistent demand for both diagnostic tests and therapeutic treatments. While food, drug, and insect allergies are important, their overall patient base is smaller compared to the widespread impact of pollen allergies.

Allergy Diagnostics and Therapeutics Market Regional Insights:

North America region is estimated to lead the market with around 31.26% share during the forecast period.

• North America is the leading region in the Allergy Diagnostics and Therapeutics market. This is due to advanced healthcare infrastructure, high per-capita healthcare spending, and strong awareness about allergy prevention and treatment. The region has a well-established presence of key pharmaceutical and diagnostic companies, which ensures easy availability of allergy tests and therapeutics.

• Additionally, the prevalence of allergies, particularly respiratory allergies, is high in North America, driving consistent demand for both diagnostics and treatments. Technological adoption, such as in-vitro testing and molecular diagnostics, is also faster here, supporting market growth and maintaining the region’s leadership position.

Allergy Diagnostics and Therapeutics Market Active Players:

• BioMérieux SA (France)
• Canon Inc. (Japan)
• Danaher (US)
• Eurofins Scientific (Luxembourg)
• HollisterStier Allergy (US)
• Minaris Medical America Inc (US)
• Omega Diagnostics Group PLC (UK)
• Siemens Healthineers AG (Germany)
• Stallergenes Greer Ltd. (UK)
• Thermo Fisher Scientific Inc (US)
• Other Active Players

Key Industry Developments in the Allergy Diagnostics And Therapeutics Market:

• In June 2025, The Stallergenes Greer Ltd. (UK) company presented strong real-world data in June 2025 on their sublingual tablet for House Dust Mite (HDM) allergy, highlighting its potential for achieving clinical remission, an exciting goal for treatment.

• In May 2024, Thermo Fisher Scientific Inc. (US) they highlighted how their sophisticated ImmunoCAP allergy diagnostic tests are crucial in guiding effective treatment decisions, helping patients get back to their activities quicker.

Overview of Allergy Diagnostics and Therapeutics Market

• The Allergy Diagnostics and Therapeutics market focuses on identifying and managing allergic conditions, which occur when the body’s immune system reacts abnormally to harmless substances called allergens. Common allergens include pollen, dust mites, food items, insect venom, and certain drugs. The market is broadly divided into diagnostics and therapeutics. Diagnostics include in-vitro tests, such as blood assays and molecular diagnostics, and in-vivo tests, such as skin prick and patch tests. These tools help detect specific allergen sensitivities accurately, enabling timely intervention.

• Therapeutics involve treatments aimed at managing or preventing allergic reactions. These include antihistamines, corticosteroids, decongestants, leukotriene inhibitors, and immunotherapy. Immunotherapy, including subcutaneous and sublingual approaches, works by gradually desensitizing the immune system to specific allergens, providing long-term relief. Biologic therapies are also emerging for severe allergic conditions, targeting immune pathways with high precision.
• Recent trends in the market focus on personalized diagnostics and treatment, leveraging molecular testing and patient-specific therapy plans. Technological advances, such as point-of-care diagnostic devices and digital health tools, improve accessibility and monitoring. North America leads the market due to advanced healthcare infrastructure, while Asia-Pacific offers high growth potential driven by rising allergy prevalence and improving medical facilities.
• Key drivers include the increasing global incidence of allergies, rising awareness, and demand for accurate diagnostics and effective therapies. Challenges include high costs, regulatory complexities, and limited access in developing regions. Overall, the market is evolving with innovation in diagnostics and therapeutics, aiming for better patient outcomes and efficient allergy management.